Alzheimer's Translation Challenge opens registration for AI-driven treatment discovery, starting spring 2027

AIPrima Mente and AlzData are launching the Alzheimer's Translation Challenge, a global AI competition to discover new therapeutic hypotheses for Alzheimer's disease. The challenge centers on a 150M cell atlas of neurons, astrocytes, and microglia across different genetic backgrounds under combinatorial perturbations, with multi-modal readouts. Top teams will have their hypotheses tested in Prima Mente's wet lab, and the data will be available through the AD workbench, Hugging Face, and Prima Mente's modeling platform.

AIThe Alzheimer's Translation Challenge, led by Primamente and AlzData with NVIDIA, Hugging Face, Nebius, Talisman Therapeutics, Ultima Genomics, Cellanome, Prime Intellect, and Boltz, is now open for registration. The competition starts in spring 2027, according to the post.

AIThe Alzheimer's Translation Challenge is built on a new atlas of 150M cells, covering neurons, astrocytes, and microglia across different genetic backgrounds under combinatorial perturbations with multi-modal readouts. The data will be made available through the AD workbench and Prima Mente's modeling platform.

AIGoodfire and PrimaMente report discovering a new class of Alzheimer's biomarkers. They are now opening a global AI competition to find new treatments, called the Alzheimer's Translation Challenge, led by PrimaMente and AlzData.